Vivos Therapeutics, Inc. Financial Ratios
VVOS|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-
Profit Margin
-74.1%
Net Income / Revenue
Asset Turnover
0.60
Revenue / Total Assets
Equity Multiplier
-16.88
Total Assets / Equity
Profitability
Liquidity
Current Ratio
0.24
Quick Ratio
0.24
Solvency
Interest Coverage
-9.06
Efficiency
Asset Turnover
0.60
Inventory Turnover
-
Days Sales Outstanding
38 days
As of FY2025 · SEC 10-K · Updated Jun 28, 2026
Earnings Quality
Accrual Ratio
+7.7%
+18.4pp YoY
Earnings include a notable portion of accrual components.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.